PRNewsWire
23 Jun 2026, 23:33 UTC · 3h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
4 claims · each scored for market impact
ADMA Biologics is accused of using channel stuffing to artificially inflate revenue growth figures. — Allegations of revenue manipulation are a severe red flag for investors as they suggest the company's growth is fake and fundamentally unsustainable.
-0.80A class action lawsuit has been filed against ADMA Biologics alleging the company misled investors regarding its business operations and lacked adequate internal controls. — Securities class actions create significant legal liabilities and often signal systemic corporate governance failures.
-0.60Reports allege ADMA failed to disclose a material related-party distribution relationship with Genesis BioPharma Services. — Undisclosed related-party transactions indicate potential conflicts of interest and lack of transparency in financial reporting.
-0.50Continue reading
6 related stories
Search tags
ADMA stock experienced two consecutive sharp declines, totaling approximately 31% over two days following a critical report by Culper Research. — The immediate market reaction confirms that the allegations have already triggered a significant loss of investor confidence.
-0.30Which stocks this story touches
The company is facing a class action lawsuit following allegations of channel stuffing and misleading investors, resulting in a significant stock price drop.
The company is mentioned as being subject to a securities class action lawsuit.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
PRNewsWire
3h ago
